Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous G-CSF-mobilized CD34+ cell transplantation for critical limb ischemia in hemodialysis patients
jRCTb030190142Recruiting
- Start
- Oct 2019
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of g-csf-mobilized autologous cd34+ cells in chronic limb-threatening ischemia (CLTI) and arteriosclerosis obliterans. Primary endpoints: Safety over 52 weeks, Major or unexpected amputation incidence and 1 more. Started Oct 2019; status: recruiting.
02
Drugs
g-csf-mobilized autologous cd34+ cells
03
Conditions
chronic limb-threatening ischemia (CLTI)arteriosclerosis obliterans
Beyond the preview
Go deeper on jRCTb030190142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTb030190142.